Literature DB >> 11292760

Characterization of binding of human lactoferrin to pneumococcal surface protein A.

A Håkansson1, H Roche, S Mirza, L S McDaniel, A Brooks-Walter, D E Briles.   

Abstract

Human lactoferrin is an iron-binding glycoprotein that is particularly prominent in exocrine secretions and leukocytes and is also found in serum, especially during inflammation. It is able to sequester iron from microbes and has immunomodulatory functions, including inhibition of both complement activation and cytokine production. This study used mutants lacking pneumococcal surface protein A (PspA) and PspC to demonstrate that the binding of human lactoferrin to the surface of Streptococcus pneumoniae was entirely dependent on PspA. Lactoferrin bound both family 1 and family 2 PspAs. Binding of lactoferrin to PspA was shown by surface colocalization with PspA and was verified by the lack of binding to PspA-negative mutants. Lactoferrin was expressed on the body of the cells but was largely absent from the poles. PspC showed exactly the same distribution on the pneumococcal surface as PspA but did not bind lactoferrin. PspA's binding site for lactoferrin was mapped using recombinant fragments of PspA of families 1 and 2. Binding of human lactoferrin was detected primarily in the C-terminal half of the alpha-helical domain of PspA (amino acids 167 to 288 of PspA/Rx1), with no binding to the N-terminal 115 amino acids in either strain. The interaction was highly specific. As observed previously, bovine lactoferrin bound poorly to PspA. Human transferrin did not bind PspA at all. The binding of lactoferrin to S. pneumoniae might provide a way for the bacteria to interfere with host immune functions or to aid in the acquisition of iron at the site of infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292760      PMCID: PMC98296          DOI: 10.1128/IAI.69.5.3372-3381.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  59 in total

1.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene.

Authors:  J Yother; G L Handsome; D E Briles
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

3.  Biochemical analysis of lactoferrin receptors in the Neisseriaceae: identification of a second bacterial lactoferrin receptor protein.

Authors:  R A Bonnah; R Yu; A B Schryvers
Journal:  Microb Pathog       Date:  1995-11       Impact factor: 3.738

4.  Identification and characterization of the transferrin receptor from Neisseria meningitidis.

Authors:  A B Schryvers; L J Morris
Journal:  Mol Microbiol       Date:  1988-03       Impact factor: 3.501

5.  Inhibition of hemolytic complement activity by lactoferrin in tears.

Authors:  R Veerhuis; A Kijlstra
Journal:  Exp Eye Res       Date:  1982-02       Impact factor: 3.467

6.  Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation.

Authors:  N B Shoemaker; W R Guild
Journal:  Mol Gen Genet       Date:  1974

7.  Identification of pneumococcal surface protein A as a lactoferrin-binding protein of Streptococcus pneumoniae.

Authors:  S Hammerschmidt; G Bethe; P H Remane; G S Chhatwal
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

8.  SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component.

Authors:  S Hammerschmidt; S R Talay; P Brandtzaeg; G S Chhatwal
Journal:  Mol Microbiol       Date:  1997-09       Impact factor: 3.501

9.  Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.

Authors:  G S Nabors; P A Braun; D J Herrmann; M L Heise; D J Pyle; S Gravenstein; M Schilling; L M Ferguson; S K Hollingshead; D E Briles; R S Becker
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

10.  Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260.

Authors:  L S McDaniel; B A Ralph; D O McDaniel; D E Briles
Journal:  Microb Pathog       Date:  1994-11       Impact factor: 3.738

View more
  39 in total

1.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

2.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

3.  Effect of apolactoferrin on experimental pneumococcal otitis media.

Authors:  Patricia A Schachern; Vladimir Tsuprun; Sebahatin Cureoglu; Patricia A Ferrieri; David E Briles; Michael M Paparella; Steven K Juhn
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-11

Review 4.  Streptococcus pneumoniae: transmission, colonization and invasion.

Authors:  Jeffrey N Weiser; Daniela M Ferreira; James C Paton
Journal:  Nat Rev Microbiol       Date:  2018-06       Impact factor: 60.633

5.  Streptococcus pneumoniae Surface Adhesin PfbA Exhibits Host Specificity by Binding to Human Serum Albumin but Not Bovine, Rabbit and Porcine Serum Albumins.

Authors:  Sreejanani Sankar; Masaya Yamaguchi; Shigetada Kawabata; Karthe Ponnuraj
Journal:  Protein J       Date:  2020-02       Impact factor: 2.371

6.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

7.  PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation.

Authors:  Jie Li; David T Glover; Alexander J Szalai; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

8.  One of two human lactoferrin variants exhibits increased antibacterial and transcriptional activation activities and is associated with localized juvenile periodontitis.

Authors:  Kabilan Velliyagounder; Jeffrey B Kaplan; David Furgang; Diana Legarda; Gill Diamond; Ruth E Parkin; Daniel H Fine
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae.

Authors:  Hazeline Roche; Bing Ren; Larry S McDaniel; Anders Håkansson; David E Briles
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Role of Pht proteins in attachment of Streptococcus pneumoniae to respiratory epithelial cells.

Authors:  Anna Kallio; Kirsi Sepponen; Philippe Hermand; Philippe Denoël; Fabrice Godfroid; Merit Melin
Journal:  Infect Immun       Date:  2014-02-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.